<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the use of reduced-intensity conditioning (RIC)-matched sibling allogeneic bone marrow stem cell transplantation as a method of establishing a graft-vs.-<z:mpath ids='MPATH_336'>leukaemia</z:mpath> (GvL) effect against myeloid disorders using a fludarabine-melphalan protocol without the use of T-lymphocyte-depleting antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>The 16 patients in this group had predominantly poor-risk <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (n=10), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/<z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n=2) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n=4) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but one patient achieved full haematopoietic engraftment </plain></SENT>
<SENT sid="3" pm="."><plain>Thirteen of 16 patients are alive and in continued complete remission on completion of this study with a median follow-up of 426 d (range 83-1524) </plain></SENT>
<SENT sid="4" pm="."><plain>The actuarial 4 yr disease-free and overall survival is 79% for both </plain></SENT>
<SENT sid="5" pm="."><plain>Only one patient relapsed following transplant, giving a relapse rate of 6% during the study period </plain></SENT>
<SENT sid="6" pm="."><plain>The treatment-related mortality was 13% (n= 2) </plain></SENT>
<SENT sid="7" pm="."><plain>Overall, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-vs.-host disease</z:e> (GvHD) occurred in 53% (8/15), with <z:hpo ids='HP_0011009'>acute</z:hpo> GvHD grade II or above occurring in 47% (7/15) </plain></SENT>
<SENT sid="8" pm="."><plain>In the 13 evaluable patients, <z:hpo ids='HP_0011010'>chronic</z:hpo> GvHD occurred in 46% (6/13), with this being extensive in three patients </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that a GvL effect can be delivered against poor-risk myeloid disorders with a low non-relapse mortality using this fludarabine-melphalan RIC protocol </plain></SENT>
</text></document>